Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Exicure ( (XCUR) ) has provided an update.
On March 19, 2026, the U.S. District Court for the Northern District of Illinois preliminarily approved a settlement of stockholder derivative claims brought on behalf of Exicure, Inc. The settlement is designed to fully and finally resolve derivative lawsuits filed in Illinois and Delaware, as well as a pre-suit litigation demand, all tied to alleged governance failures and misstatements regarding the company’s internal controls and the viability of its XCUR-FXN drug candidate during 2021.
Under the March 18, 2026 stipulation, Exicure agreed to adopt and maintain a series of corporate governance reforms addressing internal controls and oversight, with the derivative actions to be dismissed with prejudice if the settlement receives final court approval. The deal also provides for Exicure’s insurers to pay $675,000 in attorneys’ fees and expenses, and a June 2, 2026 hearing has been scheduled to determine the fairness of the settlement, which could help close a period of legal uncertainty and reputational risk for the company and its shareholders.
The most recent analyst rating on (XCUR) stock is a Sell with a $4.50 price target. To see the full list of analyst forecasts on Exicure stock, see the XCUR Stock Forecast page.
Spark’s Take on XCUR Stock
According to Spark, TipRanks’ AI Analyst, XCUR is a Neutral.
The score is primarily held down by weak financial performance (ongoing losses, unstable revenue, and heavy cash burn despite debt reduction). Technicals provide only a modest offset with improving near-term momentum, while valuation remains constrained by loss-making earnings. Corporate events are mixed, with leadership vacancies adding risk despite a positive clinical milestone.
To see Spark’s full report on XCUR stock, click here.
More about Exicure
Exicure, Inc. operates in the biotechnology sector, focusing on the development of drug candidates including XCUR-FXN. The company’s activities center on clinical research and related data collection, analysis, and reporting, with governance and internal controls over these processes being a key operational focus for its public market stakeholders.
Average Trading Volume: 32,500
Technical Sentiment Signal: Sell
Current Market Cap: $26.64M
Learn more about XCUR stock on TipRanks’ Stock Analysis page.